Interleukin-23 Antagonist [EPC]

108855 reported adverse events

Drugs of this class: GUSELKUMAB RISANKIZUMAB-RZAA TILDRAKIZUMAB-ASMN USTEKINUMAB

These side effects are most commonly reported by patients taking drugs of the Interleukin-23 Antagonist [EPC] class:

# Side effect Count
0 DRUG INEFFECTIVE 12911
1 PSORIASIS 10055
2 OFF LABEL USE 8909
3 PRODUCT DOSE OMISSION ISSUE 7617
4 FATIGUE 4968
5 PAIN 4662
6 PRODUCT USE ISSUE 4507
7 ARTHRALGIA 4425
8 HEADACHE 4096
9 RASH 3754
See all common reactions for Interleukin-23 Antagonist [EPC]

Drugs of the Interleukin-23 Antagonist [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 SWOLLEN JOINT COUNT INCREASED 550 0.6381
1 LUPUS VULGARIS 65 0.5603
2 RHEUMATIC FEVER 671 0.5527
3 ANTI-CYCLIC CITRULLINATED PEPTIDE ANTIBODY 92 0.5287
4 RED BLOOD CELL SEDIMENTATION RATE 127 0.5100
5 DEEP VEIN THROMBOSIS POSTOPERATIVE 153 0.4842
6 ANTI-CYCLIC CITRULLINATED PEPTIDE ANTIBODY POSITIVE 1665 0.4626
7 RHEUMATOID FACTOR POSITIVE 1450 0.4459
8 DUODENAL ULCER PERFORATION 946 0.2953
9 C-REACTIVE PROTEIN 54 0.2769
See all enriched reactions for Interleukin-23 Antagonist [EPC]